GlassScriptPhysician profile
Joseph Pflanzer
NPI 1336139377
$2,941.42
in general payments reported to CMS, 2019-2025
20 companies · $35.76 in 2025
The $35.76 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $646 · 2021: $956 · 2022: $514 · 2023: $150 · 2025: $35.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $776.38 | 2019-2022 | |
| Glaxosmithkline, LLC. | $496.91 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $443.62 | 2019-2023 | Dupixent |
| Pfizer INC. | $358.13 | 2019-2023 | |
| Kaleo, INC. | $188.36 | 2019-2022 | |
| Genentech USA, INC. | $167.50 | 2019-2021 | |
| Genzyme Corporation | $92.58 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $56.89 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $47.14 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $42.20 | 2022 | |
| Eyevance Pharmaceuticals LLC | $40.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $35.00 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $22.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.31 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $20.23 | 2021 | |
| Alk-Abello, INC | $18.02 | 2020 | |
| Incyte Corporation | $17.59 | 2021 | |
| Merck Sharp & Dohme LLC | $14.30 | 2021 | |
| Optinose US, INC. | $13.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Pflanzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.